Here's Holmusk. This Singapore and US-headquartered startup just raised a $45M Series B! They gather real-world clinical data to help improve care and treatment for mental and behavioral health.

Investor check. Nasdaq-listed healthcare firm Veradigm led the round. Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the investment arm of Northwell Health and other previous investors also joined in!

• They raised a $21.5M Series A in 2020.

‍

🤔 How it works

Right now, they have four solutions that bring together data, analytics, AI, digitization and more.

NeuroBlu. It's the world's largest real-world behavioral health database that comes with top-class analytics and AI tools to analyze data.

• Researchers, companies, clinicians and other industry players can generate powerful insights like never before — which can help improve clinical care and bring new treatments to market faster.

Analytics as a service. Tap into Holmusk's expertise for custom and advanced analytics in the behavioral health space.

Decision support tool. This Management and Supervision Tool (MaST) uses predictive analytics to allow healthcare providers to make better decisions.

• In practice? This can improve efficiency while giving the right care, at the right time, to the right patient.

Electronic Health Record. Their EHR platform uses data and analytics to save providers and clinicians time. At the same time, it levels up patient outcomes, gathers helpful data (from willing patients) and more.

‍

🔜 What's next?

With the $$$, they'll be growing their flagship offering, the NeuroBlu database. This includes a data partnership with Veradigm (their strategic investor) to bring cohorts of behavioral health and related data from Veradigm to their NeuroBlu database to grow NeuroBlu's dataset.